A phase I/II clinical trial showed that a vaccine targeting RHOC was well tolerated and safe in prostate cancer patients, induced effective and durable T-cell immunity, and delayed tumor metastasis and recurrence (52). This evidence concerns the gene RHOC and prostate cancer.